{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002074","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.596137+00:00","generated_at":"2026-06-20T17:26:08.244362+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel reports preliminary Q4 revenue ~$51.3M; launches REZLIDHIA for AML","bullets":["Preliminary Q4 total revenue ~$51.3M including TAVALISSE $21.9M (+24% YoY) and REZLIDHIA $0.9M (launched Dec 22).","Recognized $20M milestone from Kissei for Japan PMDA approval of TAVALISSE in chronic ITP; payment expected Q1 2023.","Cash, equivalents and short-term investments ~$58.2M as of Dec 31, 2022 (vs $125.0M a year earlier).","REZLIDHIA (olutasidenib) FDA approved for R/R AML with IDH1 mutation; commercial launch underway.","First patients dosed in Phase 1b trial of R289 (IRAK1/4 inhibitor) for lower-risk MDS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002074","json":"https://secwatch.observer/filing/0001104659-23-002074.json","markdown":"https://secwatch.observer/filing/0001104659-23-002074.md","text":"https://secwatch.observer/filing/0001104659-23-002074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923002074/0001104659-23-002074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923002074/tm232596d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:26:08.244362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7872ef8f1a6644cfd1bdfbc940e88d91e199c482","claim":"RIGEL PHARMACEUTICALS INC reported the fourth quarter ended December 31, 2022 results: revenue $51.3 million.","evidence_excerpt":"Preliminary fourth quarter 2022 Total Revenue of approximately $51.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923002074/0001104659-23-002074-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$51.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}